LeMaitre Vascular (LMAT) Expected to Post Quarterly Earnings on Tuesday

LeMaitre Vascular (NASDAQ:LMAT) is expected to post its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect LeMaitre Vascular to announce earnings of $0.81 per share and revenue of $71.4730 million for the quarter. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 5:00 PM ET.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. The business had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.48 EPS. On average, analysts expect LeMaitre Vascular to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LeMaitre Vascular Stock Up 4.2%

NASDAQ LMAT traded up $4.13 during trading on Tuesday, reaching $103.06. The company’s stock had a trading volume of 36,883 shares, compared to its average volume of 252,038. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $2.35 billion, a PE ratio of 38.14, a PEG ratio of 2.66 and a beta of 0.52. The business has a 50-day moving average price of $96.97 and a 200-day moving average price of $99.25. LeMaitre Vascular has a 1-year low of $79.00 and a 1-year high of $118.01.

Analyst Ratings Changes

LMAT has been the topic of several analyst reports. Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Zacks Research cut shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Wells Fargo & Company boosted their price target on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $112.60.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,881 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer directly owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the transaction, the insider owned 3,749 shares in the company, valued at $401,143. The trade was a 43.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 54,453 shares of company stock worth $5,906,174 over the last ninety days. Company insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LMAT. EverSource Wealth Advisors LLC bought a new stake in shares of LeMaitre Vascular in the second quarter valued at approximately $47,000. Geneos Wealth Management Inc. increased its position in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares during the period. Quarry LP raised its stake in LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after purchasing an additional 529 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in LeMaitre Vascular in the 4th quarter valued at $68,000. Finally, Kemnay Advisory Services Inc. bought a new stake in LeMaitre Vascular in the 4th quarter valued at $80,000. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.